News
MD Revolution and WellTrackONE Partner to Prepare Renaissance Health Network for Value Based Care
Read more here
Galleon Pharmaceuticals Names Joseph Oliveto as Chief Executive Officer
Read more here
Melior Discovery Receives Patent Approval from U.S. Patent and Trademark Office for New Parkinson’s Disease Drug Candidate
Read more here
HealthQx First to Receive New Certification by HCI3
Read more here
Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine
Read more here
Melior Pharmaceuticals Initiates Phase 2 Study with MLR-1023 for Type 2 Diabetes
Read more here
Merganser Biotech Inc. Raises $28 Million in a Series A Financing to Develop Hepcidin Mimetic Peptides
Read more here
Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase
One Study of Novel NMDA Receptor Antagonist d-Methadone
Read more here